About: ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.52 (+0.33%)
PROK NASDAQ ProKidney Corp.
ProKidney Corp. share price
Atividade de preço de PROK
Último preço
$ 1,470
Variação (24h)
-0,05 USD (3,29%)
Volume
814.87K
Volume (média 4 sem.)
-
Abertura
$ 1,51
Variação do dia
$ 1,43 - $ 1,53
Fechamento anterior
$ 1,52
Último negócio
29 Oct, 8:09 pm GMT+0
Atrasado
29 Oct, 8:09 pm GMT+0
PROK price performance
Atrasado
29 Oct, 8:09 pm GMT+0
quote.marketSignals